1차 출처 기록
결정급탑라인 결과
Aura Biosciences: Phase 3 CoMpass 완전 등록 완료; topline 2027년 하반기
The Phase 3 CoMpass trial of bel-sar in early choroidal melanoma is now fully enrolled with 108 patients, exceeding target. Topline data from the 15-month primary endpoint remain on track for the second half of 2027 under an FDA SPA agreement. The company has deprioritized its NMIBC program to focus resources on ocular oncology.
핵심 사실
출처 발췌
EX-99.1 2 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically deprioritized to focus company resources on ocular oncology Organizational restructuring and disciplined capital allocation strategy to align with ocular oncology focus extend expected cash runway into 1H 2029 Strengthening leadership team with appointments of experienced industry executives as Chie